Sector
PharmaceuticalsOpen
₹1,135Prev. Close
₹1,144.45Turnover(Lac.)
₹17,363.47Day's High
₹1,165.55Day's Low
₹1,123.252 Week's High
₹1,20352 Week's Low
₹567.75Book Value
₹156.19Face Value
₹1Mkt Cap (₹ Cr.)
1,15,752.13P/E
33.51EPS
34.16Divi. Yield
0.2618 May 2023
12:00 AM
Dividend
Dividend Amount: 6
Record Date: 28 Jul, 2023
9 May 2024
12:00 AM
Board Meeting
Agenda : Audited Result
18 May 2023
12:00 AM
AGM
Announcement Date: 18 May, 2023
Zituvimet XR is intended as an adjunct to diet and exercise to help improve glycemic control in adults with type 2 diabetes mellitus.
The OAI classification is the most severe of the three possible classifications assigned by the US FDA
Following this development, company’s counter slipped nearly 3% to an intraday low of ₹1,150.05 per piece on NSE.
Here are some of the stocks that may see significant price movement today: Infosys, Tata Technologies, L&T Technology Services, etc.
Notably, diroximel fumarate delayed-release capsules have garnered substantial traction in the U.S. market, generating annual sales of $5,483 million by May 2024 (IQVIA MAT).
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 100.6 | 101.2 | 102.4 | 102.4 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 15,615.9 | 13,538.2 | 13,138.1 | 12,642.1 |
Net Worth | 15,716.5 | 13,639.4 | 13,240.5 | 12,744.5 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 7,981.9 | 7,780 | 6,347.4 | 5,809.9 |
yoy growth (%) | 2.59 | 22.56 | 9.25 | 79.83 |
Raw materials | -2,870.2 | -2,351.4 | -1,951.7 | -1,695.7 |
As % of sales | 35.95 | 30.22 | 30.74 | 29.18 |
Employee costs | -1,204.9 | -1,147.3 | -1,077.4 | -826 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | 1,483.2 | 1,876 | 1,609.7 | 1,497.2 |
Depreciation | -478.7 | -451.1 | -428.9 | -293.1 |
Tax paid | -306 | -212.3 | -204.1 | -406.4 |
Working capital | 607.49 | 991.9 | 1,239 | 1,462.2 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 2.59 | 22.56 | 9.25 | 79.83 |
Op profit growth | -16.91 | 62.23 | -13.55 | 412.7 |
EBIT growth | -16.88 | 5.6 | 18.09 | 138.95 |
Net profit growth | -41.88 | 4.48 | 29.52 | 64.79 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 19,021.5 | 16,877.8 | 14,827.6 | 14,125 | 13,812.1 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 19,021.5 | 16,877.8 | 14,827.6 | 14,125 | 13,812.1 |
Other Operating Income | 525.9 | 359.6 | 282.3 | 278.5 | 441 |
Other Income | 307.1 | 186.6 | 2,583.1 | 45.6 | 113.9 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,568.65 | 123.31 | 3,76,323.69 | 867.6 | 0.86 | 5,536.99 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 4,519.8 | 76.17 | 1,19,994.45 | 531 | 0.66 | 2,259 | 507.93 |
Cipla Ltd CIPLA | 1,485.5 | 32.29 | 1,19,928.54 | 1,038.4 | 0.57 | 3,444.92 | 346.41 |
Zydus Lifesciences Ltd ZYDUSLIFE | 1,144.45 | 33.51 | 1,15,173.54 | 1,405.2 | 0.26 | 3,172.6 | 156.19 |
Dr Reddys Laboratories Ltd DRREDDY | 6,636 | 25.85 | 1,10,759.07 | 1,034.8 | 0.6 | 5,081.8 | 1,458.96 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Chairman (Non-Executive)
Pankaj R Patel
Managing Director
Sharvil P Patel
Director
Mukesh M Patel
Independent Director
Nitin Raojibhai Desai
Independent Director
Dharmishta N Rawal
Independent Director
Apurva S Diwanji
Executive Director
Ganesh N Nayak
Independent Director
Bhadresh K Shah
Company Sec. & Compli. Officer
Dhaval N Soni
Independent Director
Akhil A. Monappa
Independent Director
Upasana Konidela.
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Zydus Lifesciences Ltd
Summary
Zydus Lifesciences Ltd. (Formerly known as Cadila Healthcare Ltd.) is one of the leading innovation driven pharmaceutical companiesin India with presence across the pharmaceutical value chain including innovating (research & development), manufacturing,marketing and selling of finished dosage human formulations (generics, branded generics and specialty formulations, includingbiosimilars and vaccines), Active Pharmaceutical Ingredients (APIs), animal healthcare products and consumer wellness products. The Company operate manufacturing facilities at Ahmedabad, Ankleshwar and Vadodara in Gujarat, Ponda in Goa, Raigad in Maharashtra and Solan in Himachal Pradesh.Founded by the Late Promoter, Mr. Ramanbhai B. Patel, the Company was incorporated in May, 1995 and converted into a Public Limited Company in July, 1996. The Companys operation includes pharmaceuticals, which includes human formulations, veterinary formulations and bulk durgs, diagnostics, herbal products, skin care products and OTC products. In the year 1996, the Company made a strategic alliance with Gulin Pharma of China and launched Falcigo in India, which is an anti-malarial segment. In May 2000, the company acquired formulation business of Recon Ltd, which strengthens the company in the southern market. In the year 2001, they acquired German Remedies which was the largest M&A in the Indian Pharmaceutical sector and in the same year, they entered into a joint venture with US based Onconova for collaborative research
Read More
What is the Zydus Lifesciences Ltd share price today?
The Zydus Lifesciences Ltd shares price on N/A is Rs.₹1150.75 today.
What is the Market Cap of Zydus Lifesciences Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Zydus Lifesciences Ltd is ₹115792.38 Cr. as of 22 Jul ‘24
What is the PE and PB ratio of Zydus Lifesciences Ltd?
The PE and PB ratios of Zydus Lifesciences Ltd is 33.51 and 7.33 as of 22 Jul ‘24
What is the 52 Week High and Low of Zydus Lifesciences Ltd?
The 52-week high/low is the highest and lowest price at which a Zydus Lifesciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Zydus Lifesciences Ltd is ₹564.05 and ₹1203.2 as of 22 Jul ‘24
What is the CAGR of Zydus Lifesciences Ltd?
Zydus Lifesciences Ltd's CAGR for 5 Years at 38.03%, 3 Years at 21.41%, 1 Year at 88.40%, 6 Month at 59.01%, 3 Month at 24.12% and 1 Month at 6.62%.
What is the shareholding pattern of Zydus Lifesciences Ltd?
The shareholding pattern of Zydus Lifesciences Ltd is as follows:
Promoters - 74.98 %
Institutions - 18.22 %
Public - 6.80 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
